CARL
CARLSMED, INC.
There isn't enough reported data to score CARL yet.
CARL Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
CARL's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
CARL PE Valuation
CARL has no meaningful PE right now: it lost money over the past year.
CARL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect CARL's revenue to grow and its profitability to improve, with its earnings holding steady.
CARL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$2.38 | +$2.57 |
CARL is still losing money, but far less than before: $2.38 per share over the past year, against $4.95 at its worst in late 2024.
CARL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $21.6M | +65% |
| Q2 2026 | $18.9M | +57% |
| Q1 2026 | $16.1M | +58% |
| Q4 2025 | $15.2M | +61% |
| Q3 2025 | $13.1M | +98% |
| Q2 2025 | $12.1M | +99% |
| Q1 2025 | $10.2M | +100% |
| Q4 2024 | $9.4M | +117% |
CARL's revenue has grown year over year every quarter since late 2024: $22M last quarter, up 65% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -59% | +10 points |
| Q2 2026 | -58% | -4.5 points |
| Q1 2026 | -58% | -1.4 points |
| Q4 2025 | -61% | +401 points |
| Q3 2025 | -69% | -187 points |
| Q2 2025 | -54% | +50 points |
| Q1 2025 | -56% | +49 points |
| Q4 2024 | -463% | -338 points |
CARL's operating margin was −59% last quarter, up 10 points from the same quarter a year ago.
CARL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$9M | -$339K |
| Q1 2026 | -$13.1M | -$4.7M |
| Q4 2025 | -$5.4M | -$1.1M |
| Q3 2025 | -$8.6M | -$986K |
| Q1 2025 | -$8.4M | -$930K |
CARL has burned cash in almost every quarter: −$35M over the past year, against −$29M the year before.
CARL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +112K shares |
| 1 year | +495% | +22.7M shares |
CARL has 27M diluted shares, up 495% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
CARL Net Leverage
CARL's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CARL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 63.2 | Neutral |
| Stochastic | 57.0 | Neutral |
CARL's weekly RSI is 63 (neutral) and its Stochastic is 57 (neutral).
CARL PE vs Healthcare Sector
CARL has no meaningful PE right now: it lost money over the past year.
CARL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $14.8 | 17% above |
| 20 week MA | $14.2 | 22% above |
| 50 week MA | $12.6 | 37% above |
CARL is in an uptrend: it's above all three of its weekly moving averages, and 37% above its 50-week average.
CARL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $14.5 | $13.7 | -5.4% |
| 2026 YTD | $13.7 | $17.3 | +26% |
CARL has finished every year since 2025 lower, and it's up 26% so far in 2026.